Drug Profile
Fosnetupitant - Helsinn
Alternative Names: Arokaris; Pro-NETULatest Information Update: 24 Aug 2023
Price :
$50
*
At a glance
- Originator Helsinn
- Developer Helsinn; Taiho Pharmaceutical
- Class Antiemetics; Piperazines; Pyridines; Small molecules
- Mechanism of Action Neurokinin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Chemotherapy-induced nausea and vomiting
Most Recent Events
- 24 Aug 2023 Phase-I clinical trials in Chemotherapy-induced nausea and vomiting (Prevention) in USA (IV) before August 2023 (Helsinn pipeline; August 2023)
- 28 Aug 2022 No recent reports of development identified for phase-I development in Chemotherapy-induced-nausea-and-vomiting(Combination therapy, In volunteers) in Switzerland (IV, Liquid)
- 28 Mar 2022 Registered for Chemotherapy-induced nausea and vomiting (Combination therapy, Prevention) in Japan (IV)